Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Fomivirsen sodium; ISIS 2922; Vitravene

Latest Information Update: 15 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Isis Pharmaceuticals; Pacira Pharmaceuticals
  • Class Antisense oligonucleotides; Antivirals; Thionucleotides
  • Mechanism of Action RNA binding protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cytomegalovirus infections
  • New Molecular Entity Yes

Highest Development Phases

  • Market Withdrawal Cytomegalovirus infections

Most Recent Events

  • 09 Apr 2019 Pacira Pharmaceuticals is now called Pacira BioSciences
  • 11 Jan 2016 Ionis Pharmaceuticals completes a phase I/II trial in Cytomegalovirus infections in USA (Ophthalmic) before June 2005 (NCT00002187)
  • 18 Nov 2005 Fomivirsen has received Orphan Drug Status for CMV-induced retinitis in AIDS patients in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top